| Literature DB >> 32244421 |
Olga Shcherbatova1, Dmitry Grebennikov1,2,3, Igor Sazonov4, Andreas Meyerhans5,6, Gennady Bocharov1,2,3.
Abstract
There are many studies that model the within-host population dynamics of Human Immunodeficiency Virus Type 1 (HIV-1) infection. However, the within-infected-cell replication of HIV-1 remains to be not comprehensively addressed. There exist rather few quantitative models describing the regulation of the HIV-1 life cycle at the intracellular level. In treatment of HIV-1 infection, there remain issues related to side-effects and drug-resistance that require further search "...for new and better drugs, ideally targeting multiple independent steps in the HIV-1 replication cycle" (as highlighted recently by Teldury et al., The Future of HIV-1 Therapeutics, 2015). High-resolution mathematical models of HIV-1 growth in infected cells provide an additional analytical tool in identifying novel drug targets. We formulate a high-dimensional model describing the biochemical reactions underlying the replication of HIV-1 in target cells. The model considers a nonlinear regulation of the transcription of HIV-1 mediated by Tat and the Rev-dependent transport of fully spliced and singly spliced transcripts from the nucleus to the cytoplasm. The model is calibrated using available information on the kinetics of various stages of HIV-1 replication. The sensitivity analysis of the model is performed to rank the biochemical processes of HIV-1 replication with respect to their impact on the net production of virions by one actively infected cell. The ranking of the sensitivity factors provides a quantitative basis for identifying novel targets for antiviral therapy. Our analysis suggests that HIV-1 assembly depending on Gag and Tat-Rev regulation of transcription and mRNA distribution present two most critical stages in HIV-1 replication that can be targeted to effectively control virus production. These processes are not covered by current antiretroviral treatments.Entities:
Keywords: HIV-1; antiviral targets; intracellular replication; mathematical model; sensitivity analysis
Year: 2020 PMID: 32244421 PMCID: PMC7238236 DOI: 10.3390/pathogens9040255
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Biochemical scheme of the HIV-1 replication cycle.
Figure 2Scheme of HIV-1 entry into the host cell.
Estimates of the Calibrated Model Parameters.
| Parameter | Description | Value | Range, Relev. Refs. |
|---|---|---|---|
|
| rate of virion binding to CD4+ T cell membrane |
| |
|
| clearance rate of free mature virions |
| |
|
| degradation rate of bound virions |
|
|
| [ | |||
|
| rate of virion fusion with the cell |
| |
|
| reverse transcription rate |
| |
|
| degradation rate of RNA in cytoplasm |
| [ |
|
| degradation rate of DNA in cytoplasm |
| |
|
| transport rate of DNA from cytoplasm to nucleus |
| [ |
|
| degradation rate of DNA in nucleus |
| [ |
|
| integration rate |
| |
|
| degradation rate of DNA integrated into chromosome | 0.00002 | [ |
|
| cell intrinsic rate of basal transcription | 15 | [ |
|
| level of transcription induced by Tat transactivation | 1500 | |
|
| threshold for half-maximal boosting of transcription by Tat | 1000 molec. | [ |
|
| threshold for half-maximal boosting on export of | 77,000 molec. | |
|
| inhibitory effect of Rev on the splicing rates implying their 1 / ( 1 − β ) -fold reduction at saturation level of Rev | 0.9 | |
|
| transport rate of | 2.8 | |
|
| rate of |
| |
|
| rate of |
| [ |
|
| rate of splicing for full-length virus RNA |
| |
|
| rate of splicing for singly spliced virus RNA |
| |
|
| degradation rate of |
| |
|
| degradation rate of protein gp160 |
| [ |
|
| degradation rate of protein |
| |
|
| degradation rate of Tat protein |
| |
|
| degradation rate of Rev protein |
| |
|
| fraction of | ||
|
| — | 0.05 | [ |
|
| — | 0.95 | [ |
|
| — | 0.64 | [ |
|
| — | 0.025 | [ |
|
| — | 0.2 | |
|
| rate of mRNA to proteins translation | 524 proteins/mRNA/h | |
|
| degradation rate for the membrane anchored protein Gag-Pol |
| [ |
|
| degradation rate for the membrane anchored protein Gag |
| [ |
|
| degradation rate for membrane associated gp160 (Env) |
| [ |
|
| rate of protein |
| |
|
| incorporation rate of molecules into pre-virion complexes | 8 | |
|
| number of viral RNA transcripts in a new virion | 2 | [ |
|
| number of Gag molecules in a new virion | 5000 | |
|
| number of Gag-Pol molecules in a new virion | 250 | |
|
| number of gp160 molecules in a new virion | 24 | |
|
| degradation rate of assembled pre-virion complex |
| |
|
| budding rate of new virions |
| |
|
| degradation rate for budded immature viral like particle |
| |
| (= clearance rate of mature virions) | |||
|
| maturation rate |
| [ |
Figure 3HIV-1 reverse transcription and integration.
Figure 4Biochemical events underlying transcription, splicing, export and translation of HIV-1.
Figure 5Assembly, budding and maturation.
Figure 6Numerical solution of the calibrated model for the parameter values given in Table 1.
Figure 7The normalized sensitivity of the functional to the parameters which have (left) negative effect and (right) positive effect on HIV-1 production.
The most sensitive processes on which the net HIV-1 production depends.
| Processes Having Negative Effect on |
|
| Processes Having Positive Effect on |
|
|
|---|---|---|---|---|---|
| Gag contribution to virion assembly |
| 1810 | Transcription induced by Tat |
| 1971 |
| Degradation of free and mature virions |
| 1721 | Translation of Gag molecules |
| 1811 |
| Transport of genomic mRNA to membrane |
| 1697 | Assembly of pre-virion complexes |
| 1810 |
| Degradation of RNA during RT |
| 602 | Transport of proviral DNA to nucleus |
| 938 |
| Degradation of assembled complexes |
| 364 | Inhibitory effect of Rev on splicing rates |
| 895 |
| Degradation of DNA during RT |
| 268 | Reverse transcription |
| 781 |
| Splicing of full-length genomic RNA |
| 262 | Integration of proviral DNA |
| 712 |
| Degradation of budded immature particles |
| 242 | Export of full-length genomic RNA |
| 415 |
| Degradation of genomic mRNA |
| 161 | Budding of immature particles |
| 412 |
| Tolerance of mRNA export and |
| 118 | Maturation of budded particles |
| 285 |
| splicing to Rev-mediated regulation | Binding of virions to the cell membrane |
| 250 | ||
| Fusion of virions with the cell |
| 166 | |||
| Translation of Rev molecules |
| 118 | |||
| Splicing of singly spliced RNA |
| 104 |
Figure 8Intracellular replication of HIV-1 with the identified processes showing the strongest impact on virion production. Blue boxes indicate the stages which most strongly affect the virus production. The sets indicated in boxes 1, 2, 3, 4, 5 are the processes with normalized sensitivity values larger than 500 for which effective inhibitors do not exist. The numbers refer to the sensitivity strength with 1 referring to the more strong and 5 to the less strong sensitivity.